Why Is TELIX PHARMACEUTICAL ADR (TLX) Stock Down Today?

Why TLX stock is down today

Telix Pharmaceuticals ADR (TLX) fell 7.13% to $11.92 in early trading on Monday. The stock opened with a -3.3% gap from its prior close and has continued to trade lower throughout the session. The decline follows a recent price increase driven by the FDA approval of its Pixclara imaging drug, which had pushed the stock to a 52-week high earlier this month.

What Happened

The stock opened at $12.41, below the previous session’s close of $12.83, and has since fallen to $11.91. The session low reached $11.79 at 9:35 AM ET. Trading volume has been relatively low at 0.1 million shares, which is 40% of the 3-month daily average. This suggests limited participation in the move. H.C. Wainwright recently reaffirmed a $20 price target for Telix, but the stock has not held above its intraday high of $12.50. The stock has now printed five fresh 52-week lows on Monday, indicating a potential shift in sentiment following a recent rally.

What The Data Shows

Telix has a market capitalization of $4.0 billion and trades at a P/E ratio of 134.5, reflecting its high-growth profile. The company reported a 33.5% year-to-date revenue increase and a net margin of 3.8%. Its beta of 0.60 suggests it is less volatile than the broader market. The stock has moved up 10.2% over the last eight sessions, rising from $11.74 to $12.94. Recent insider transactions include a $20,000 purchase by Group CFO Darren Charlton on September 7, 2026, and another on September 14, 2026.

What To Watch

Telix does not have an upcoming earnings date listed. Investors should monitor the breadth of coverage and any further analyst commentary as the stock continues to trade near its 52-week range of $6.28 to $13.11.